EXELIXIS INC (EXEL:NASDAQ)
$44.27 -1.14 (-2.5105%)
Analysed EXELIXIS INC (EXEL:NASDAQ) News Sources
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry
31-03-2026
yahoo.com
Lilly’s AI commitment expands through deal with Insilico
30-03-2026
biopharmadive.com
RBC Capital Lowers Exelixis (EXEL) Price Target to $43
28-03-2026
yahoo.com
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion
16-03-2026
yahoo.com
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink
16-03-2026
marketbeat.com
Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference
16-03-2026
marketbeat.com
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference
16-03-2026
marketbeat.com
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound?
12-03-2026
yahoo.com
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade
28-02-2026
fool.com
Is It Too Late To Consider Exelixis (EXEL) After Its Surging Share Price?
25-02-2026
yahoo.com
What is the current price of EXELIXIS INC (EXEL:NASDAQ)?
The current price of EXELIXIS INC (EXEL:NASDAQ) is $44.27.
EXELIXIS INC (EXEL:NASDAQ) absolute price change since previous trading day?
The absolute price change of EXELIXIS INC (EXEL:NASDAQ) since the previous trading day is $-1.14.
EXELIXIS INC (EXEL:NASDAQ) percentage price change since previous trading day?
The percentage price change of EXELIXIS INC (EXEL:NASDAQ) since the previous trading day is -2.5105%.
What is the most recent average sentiment score for EXELIXIS INC (EXEL:NASDAQ)?
The most recent average sentiment score for EXELIXIS INC (EXEL:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for EXELIXIS INC (EXEL:NASDAQ)?
The most recent sentiment for EXELIXIS INC (EXEL:NASDAQ) is .
SEC-8K** Filing Available For EXELIXIS INC (EXEL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.